Corner Therapeutics
A USA-based immunotherapy company developing novel vaccines against cancer and infectious diseases.
Corner is utilising its novel dendritic cell stimuli platforms to create therapeutic cancer and infectious disease vaccines that could provide life-long immunity.
In Q2 2024, the company announces $54 million in Series A funding, led by Ziff Capital Partners and including Cockrell Interests, Tanis Ventures, and Sandia Holdings. The company hopes to use the proceeds to initiate its first clinical study in 2025.
Latest Corner Therapeutics News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze